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Introduction
The very process of de-regulated oncogene expression during cancer development also sensitizes cancer cells to apoptotic signals (7, 8, 12) . De-regulated oncoproteins like E1a and c-Myc promote apoptosis by activiating multiple downstream pro-apoptotic effector pathways (9, 10) . Additional mechanisms of sensitizing cancer cells to apoptosis by an activated oncoprotein have been described (6, 21) . For example, E2F sensitized cells to apoptosis through down-regulation of anti-apoptotic signals (21) . Here we show that cancer cells can also be sensitized to apoptosis by up-regulating the expression levels of RKIP (Raf kinase inhibitor protein) .
RKIP was originally identified as an interacting partner of Raf-1 and a negative regulator of the mitogenactivated protein kinase (MAPK) cascade initiated by Raf-1(32). RKIP also inhibits NF-κB signaling by negatively modulating the activating phosphorylation of IKKα and IKKβ via upstream kinases (33). Although the molecular mechanism of how RKIP inhibits the Raf and NF-κB signaling pathways has been partially delineated, little is known about the biological relevance of the inhibition of these pathways by RKIP. In addition to these functions, we presently demonstrate the rapid up-regulation of RKIP during induction of chemotherapytriggered apoptosis in human prostate and breast cancer cells. However, in DNA damage agent-resistant cancer cells treatment with the drugs does not up-regulate RKIP expression. Ectopic expression of RKIP sensitizes resistant cells to undergo apoptosis. Down-regulation of RKIP expression confers resistance to 9-nitrocamptothecin (9NC) by releasing its inhibitory constraint on two major survival pathways in cancer cells.
Our studies suggest that RKIP represents a novel apoptotic marker in human cancer cells.
by guest on October 30, 2017 http://www.jbc.org/ Downloaded from driven by the constitutive TK promoter was included in all transfection experiments as an internal control to correct for transfection efficiency. Dual luciferase assays were performed using a kit obtained from Promega.
Immunoblot Analysis. Total cell extracts were prepared as previously described (3) , and protein concentrations of lysates were determined using the Bradford assay kit (BioRad). Proteins (10-50 µg) were separated by SDS-PAGE and electrophoretically transferred from the gel to nitrocellulose membranes (Amersham). Proteins recognized by the antibodies were detected by enhanced chemiluminescence reagents (Amersham). The PARP monoclonal antibody was from Zymed Laboratories (San Francisco, CA); the IκBα antibody was from Upstate Biotechnology (Lake Placid, NY); MEK was from Santa Cruz (Santa Cruz, CA); Phospho-MEK and phospho-IκBα antibodies were from Cell Signaling (Beverly, MA); the antibody to actin was purchased from Sigma. The antibody to RKIP has been described (32). The antibody to caspase-8 (C15) was generously provided by Dr.
Peter H. Krammer, DFKZ, Heidelberg, Germany
Immunohistochemistry of Human Tissue
Radical prostatectomy specimens were obtained at the time of surgery from prostate cancer patients at the University of Michigan and frozen in liquid nitrogen within 30 minute after surgical excision as previously described (22) . Histologic confirmation of both tumor and normal regions of each prostate gland and tumor grading were performed as previously described (26) . Written informed consent was obtained from all patients and all tissue procurement was approved by the University of Michigan Institutional Review Board. Frozen tissue block were sectioned on a cryostat and frozen sections were placed on slides, which were immersed in acetone at 4°C for 15 minutes and air dried for 30 seconds, then stored in PBS until immunostaining was performed. RKIP protein expression was detected using a rabbit polyclonal anti-RKIP (1:400 dilution; Upstate Biotechnology, Lake Placid, New York) followed by the streptavidin-biotin method, which included horseradish peroxidase and diaminobenzidine chromogen (Histostain Kit, Zymed, San Francisco). Immunostaining intensity was scored by an urologist (Y.K.) blinded to Gleason score, tumor size or clinical outcome as previously described (26) . Briefly, the spectrum of staining intensity in all the samples was evaluated and then each sample by guest on October 30, 2017 http://www.jbc.org/ Downloaded from scored as negative (score 1), weak (score 2), moderate (score 3) or strong (score 4) based on the amount of stain detected.
Cell death/survival analyses At various times following treatment with the indicated drugs, adherent and floating cells were collected for analysis. Apoptosis was assayed by staining the cells with annexin-V and 7-amino-actinomycin D (7-AAD) and quantified by a Guava personal cytometer (Guava, Burlingame, CA).
Alternatively, total cell extracts were prepared and analyzed for both PARP and caspase 8 cleavage by RT-PCR assays. DU145 cells were treated with 9NC for 24 h. Total RNA was isolated and 1 µg used for firststrand synthesis, which then served as a template for PCR reactions using a 1st Strand cDNA Synthesis kit purchased from Boehringer Mannheim (Indianapolis, IN). The RKIP PCR primers were hrkip1, sense in exon 1, 5'-CCT CGC CAT GCC GGT GGA CC-3'; hrkip2, antisense in exon 1, 5'-CCG CCG CCC CGG CGT AGG TG-3'; hrkip3, sense in exon 2, 5'-GGA TGC TCC CAG CAG GAA GG-3'; hrkip4, antisense in exon 3, 5'-CCT TGG GAG GCC CCG AGC CC-3', the β-actin PCR primers were 5'-ATC TGG CAC CAG ACC TTC TAC AAT GAG CTG CG-3' and 5'-CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC-3'. The PCR products were analyzed on a 2% agarose gel containing ethidium bromide.
Retrovirus-mediated gene transfer pBabe-puro-based retroviral constructs encoding p65, RafCAAX, and
CrmA were used to generate retroviruses using the 293GPG packaging cell line as described (19) . Infected cells were cultured in puromycin selection medium for 3 days and drug-resistant cells were pooled. The percentage of retrovirus-infected cells ranged from 60-80%, as estimated in parallel infections using retroviruses expressing GFP. Expression of relevant genes was confirmed by immunoblotting.
Results
The DU145 human prostate carcinoma cell line undergoes extensive apoptosis when treated with the clinically relevant anti-cancer drug, 9NC (3, 4 1a , right panel and 1b, lower panels).
As NF-κB is a regulator of apoptosis (2), we analyzed both cytoplasmic and nuclear extracts of 9NC-treated DU145 and RC1 cells for NF-κB activation. NF-κB activity was consistently up-regulated as indicated by increased expression of an NF-κB reporter and IκB degradation in 9NC treated cells (Fig. 1c, prepared from cells prior to and after 9NC treatment, but RKIP expression was robustly increased in 9NC treated DU145 cells (insets in Fig. 1c ). To investigate whether the induction of RKIP expression resulted from a DNA damage response or a consequence of apoptosis, we blocked the 9NC-mediated apoptosis in DU145 cells with the pan-caspase inhibitor Z-VAD-FMK (1). As expected, inhibiting the activities of caspases, the major executors of apoptosis in mammalian cells, protected DU145 cells from apoptosis (Fig. 1g) . Importantly, Z-VAD-FMK treatment did not block 9NC-induced RKIP expression, indicating that induction of RKIP was not the consequence of apoptosis (Fig. 1g) .
We have recently shown that unlike DU145, RC1 cells contain a mutated topoisomerase-I, and this has been associated with development of resistance to 9NC (29) . To determine if 9NC introduces DNA strands breaks in RC1 cells, we monitored the extent of H2A.X phosphorylation with H2A.X phospho-specific antibodies. H2A.X is a histone variant, which is rapidly phosphorylated at serine 139 in response to DNA damage and is indicative of a cell committed to the apoptotic pathway (25) . Following treatment with 9NC, the histone variant H2A.X was robustly phosphorylated in DU145 cells, but remained unphosphorylated in RC1 cells (Fig. 1d) . The data described above therefore suggests that RKIP is the down stream target of a DNA damage-mediated signaling pathway initiated by 9NC and this pathway is defective in RC1 cells.
The known protective effects of NF-κB, the strong induction of RKIP in the 9NC treated DU145 cell line, and the loss of this effect in the RC1 cell line imply that one biological role of RKIP may be to exert a repressive effect on the NF-κB pathway in certain situations, allowing apoptosis to proceed. To assess whether RKIP was functionally linked to the apoptosis resistant phenotype, we transfected RC1 cells with an RKIP expression vector and subsequently treated with 9NC. Expression of RKIP re-sensitized the cells to 9NC-mediated apoptosis ( Fig. 1e-f ). It is important to note that overexpression of neither RKIP nor IκB-SR alone fully induces apoptosis in RC1 cells (Fig. 1e , lower panels)
To determine whether induction of RKIP expression is chemotherapeutic agent specific, we examined the effects of other DNA damaging agents on DU145 cells. Both cisplatin and etoposide up-regulated RKIP expression and caused apoptosis in DU145 cells (Fig 2a-b) . Remarkably, the onset of apoptosis, as indicated by of cleavage of caspase 8 and PARP, and evaluating binding to annexin V (Fig. 3c-e) . Taken together, these data strongly suggest that RKIP is the cause of 9NC-mediated apoptosis in DU145 cells. We reasoned that if RKIP is the cause of apoptosis in DU145 cells, we should be able to protect these cells from apoptosis by blocking the 9NC-triggered increase in RKIP expression. Indeed, down-regulation of RKIP expression by anti-sense RKIP expression vector and RKIP siRNA blocked 9NC-induced apoptosis in DU145 as measured by PARP cleavage of and by the number of viable cells (Fig. 3f-h ).
The NF-κB and Raf signal pathways are both important in determining cell survival in many different cell types (2, 17, 18, 28) . The significance of these signal pathways in DU145 cell survival was investigated by a loss-of-function approach. We interfered the NF-κB and Raf signaling pathways in DU145 cells by ectopically expressing either IκB-SR or a dominant-negative mutant of Raf (RafDN) (14). As expected, we observed inhibition of an NF-κB reporter and down-regulation of the Raf signaling pathway as measured by MEK dephosphorylation in IκB-SR or RafDN mutant transfected cells (data not shown). Importantly, down-regulation of either pathway was accompanied by an increase in apoptosis as measured by a reduction in the number of viable cells (Fig. 4a) . It is also noteworthy that the pro-apoptotic effects of either IκB-SR or RafDN are comparable to that of the well-characterized pro-apoptotic protein t-Bid in DU145 cells (Fig. 4a) . Conversely, ectopic expression of the activated Raf (Raf-CAAX) by retroviral transduction partially protected the DU145 cells from 9NC-induced apoptosis (Fig. 4b, row 2) . The survival promoting effects of Raf-CAAX is comparable to ectopic expression of CrmA, a known inhibitor of caspase 8 (Fig. 4b, row 6 ) (34). Unexpectedly, expression of p65 or p52 either failed to protect or protect minimally the DU145 cells from apoptosis ( Fig. 4b rows 3-4) . We speculate that the failure is probably because neither p65 nor p52 is constitutive active. In addition, we observed that the expression levels obtained with retroviral transduction are not as high as transient expression driven by CMV promoter (data not shown). Nonetheless the expression of p65 augmented the survival effects of activated
Raf resulting in total protection of cell from apoptosis (Fig. 4b, row 5 ) and thus support our argument that NF-κB is an important survival factor in DU145 cells. We next investigated the possibility that RKIP induces apoptosis by antagonizing either one of the two survival pathways. As shown in Fig. 4 c-d , RKIP-induced apoptosis was relieved by overexpression of the p65 subunit of NF-κB or the constitutively active form of Raf (BXB). The effects of p65 and BXB on RKIP-induced apoptosis are not due to a lower RKIP expression in combined transfection as RKIP levels are similar as detected by immunoblotting (Fig. 4d, lower panel) . This indicates that NF-κB as well as Raf up-regulation has an apoptosis sparing effect. In agreement with our hypothesis that RKIP induces apoptosis by antagonizing with Raf and NF-κB signaling, overexpression of RKIP in DU145 cells diminished the phosphorylation of both MEK and IκB-α (Fig. 4e ).
An aberrant up-regulation of NF-κB activity is often observed in breast cancer cell lines (13, 23) . Nuclear extracts prepared from normal, untransformed breast epithelial 578Bst cells displayed low levels of NF-κB DNA binding activity, whereas elevated levels of activity were detected in extracts from the breast tumor cell line 578T (28) . Inhibition of this NF-κB activity by microinjection of IκB protein into breast cancer cell lines induced apoptosis (28) . Consistent with these studies, we also observed an elevated levels of NF-κB activity as measured by the phosphorylation of IκB (Fig. 5a ). In agreement with the observed inhibitory role of RKIP on NF-κB signaling (33), higher levels of NF-κB activity in 578T correlated with decreased expression of RKIP (Fig. 5a ).
The converse was observed in the normal cell line 578Bst (Fig. 5a) . Consistent with the decreased levels of RKIP, the Raf signaling pathway was comparatively elevated in 578T, as measured by the activities of transcriptional factor AP1 and phosphorylation of MEK (Fig. 5a ). Next we determine if the expression levels of RKIP can be up-regulated by DNA damaging agents. Unlike the prostate cancer DU145 cells, RKIP protein expression in 578T did not change following treatment with the DNA damaging drugs 9NC, cisplatin, and etoposide (Fig. 5c) . Furthermore, 578T cells did not undergo apoptosis after 9NC treatment as indicated by the lack of PARP cleavage and binding to annexin V (Fig. 5b-c) . The non-responsiveness to DNA-damage induced apoptosis was not due to mutations in the apoptotic pathways in 578T cancer cells, since apoptosis was induced by another pro-apoptotic drug, taxol (Fig. 5b-c) . Finally, restoring the expression levels of RKIP by ectopic expression triggered apoptosis (Fig. 5d) (Fig. 5e-h ).
Discussion
The underlying mechanism determining whether a cell will die after DNA damage is complex (24) . However, it is known that the threshold for the activation of apoptosis in response to DNA damage is set lower in cancer cells than their normal counterparts (7, 8, 12) . Although it is axiomatic that the pro-apoptotic trait of cancer cells and stained with X-gal. Viable blue-stained cells were determined as described in Fig. 3d . 
